Regulation

Pandemic could give advantage to newly approved MS latecomer ofatumumab

Novartis’ once-monthly anti-CD20 mAb is only auto-injectable MS drug targeting B cells 

With FDA’s approval of Kesimpta ofatumumab for multiple sclerosis, Novartis could become the latest company to reap the added benefits of launching a drug with a convenient route of administration